Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win

Executive Summary

Following the failure late last year of Regeneron's combination of Eylea with nesvacumab, a Phase II success for the Swiss major's RG7716 is a boost for the theory that a VEGF/Ang-2 combo therapy can transform the treatment of certain eye diseases.

You may also be interested in...



Solid STAIRWAY Leads Roche To Phase III Study Of Faricimab In Wet AMD Trial

Roche unveiled positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD).

Exonate Sees Alternative mRNA Splicing Inhibitors As New Eye Disease Therapies

Emerging Company Profile: Inhibitors of VEGF-A alternative mRNA splicing could deliver a step-change in the treatment of retinal eye diseases, hopes UK start-up Exonate.

Stock Scan February 2018: Wet But Above Water

The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel